Patrick Forde · @FordePatrick“RAS(ON)i daraxonrasib in pretreated RAS mutant (non G12C) lung cancer, high grade tox in 54% incl 2.9% deaths. Tumor responses in 31-37% of pts, PFS 8.3m. So far not the breakthrough in lung cancer that it has been in pancreatic cancer #lcsm”
View post ↗See the full daraxonrasib NSCLC KOL discussion on KOL Pulse →The SARON trial will present data at ESMO26 on consolidation radiotherapy for synchronous oligometastatic NSCLC. The thoracic oncology community is also anticipating data from WCLC26, which will feature results from two B7-H3 ADCs in SCLC, trials addressing the role of prophylactic cranial irradiation (PCI) in the MRI era, and the REZILIENT-3 trial of zipalertinib.
“Nine trials in two Presidential Symposia will answer questions we have been arguing about for a decade: whether PCI survives the MRI era in SCLC, whether topotecan is finished as a comparator once two B7-H3 ADCs report side by side, and whether exon 20 gets one standard or two.”
— @GlopesMd · WCLC26 Preview · View post ↗
“At ASCO26 we saw 1L Sunvozertinib /WU-KONG 28) data, perhaps similar in activity to chemo+amivantamab (PAPILLON), different side effects Will Zipalertinib be better, equivalent or worse?”
— @tnewsomdavis · REZILIENT-3 Trial · View post ↗📌 Amplified by @KolPulseAI
“A must-read for every SCLC-warrior exemplifying that the combination of #TCEs and #ADC holds promise for deep and durable responses in ES-SCLC”
— @g_mountzios · ADCs and TCEs in SCLC · View post ↗📌 Amplified by @KolPulseAI
The FDA granted accelerated approval to the oral SERD camizestrant with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer upon detection of an ESR1 mutation during first-line aromatase inhibitor and CDK4/6i therapy. Based on the SERENA-6 trial, the FDA describes it as the first approval of a cancer therapy guided by a resistance mutation detected in ctDNA before imaging shows progression, with Guardant360 CDx authorized as the companion diagnostic. Separately, summaries of NCCN guidelines for axillary management are being shared, outlining criteria for performing or omitting SLNB and ALND.
“switching therapy when an ESR1 mutation appears in ctDNA, before scans show progression. This is resistance defined, drugged, and tracked at the bedside.”
— @NeilVasan · Molecular Resistance Strategy · View post ↗📌 Amplified by @KolPulseAI
“On April 30, ODAC voted 3-6 against.”
— @DrChoueiri · Regulatory Context · View post ↗
“Will you start monitoring for ESR1 mutations with repeat ctDNA testing during 1L treatment?”
— @PTarantinoMD · Clinical Practice Implications · View post ↗📌 Amplified by @KolPulseAI
“Con: Accelerated approval, OS immature, confirmatory trials required. Boxed warning for irregular heart rhythm with certain concomitant meds, plus bradycardia.”
— @drsarahsam · Camizestrant Approval Details · View post ↗
“• 1–2 positive SLNs + appropriate BCS/RT → no ALND”
— @dr_yakupergun · NCCN Axillary Guidelines · View post ↗Bristol Myers Squibb voluntarily withdrew the accelerated approval of adagrasib plus cetuximab for previously treated KRAS G12C-mutated metastatic colorectal cancer, and the FDA approved the withdrawal effective September 1. The action follows the confirmatory phase III KRYSTAL-10 trial missing its primary endpoints of progression-free survival (7.5 vs 8.1 months) and overall survival (21.6 vs 21.7 months) versus standard chemotherapy, as presented at ESMO GI 2026. While the trial was negative, some physicians noted the combination's higher response rate in KRYSTAL-10 (47% vs 16%) and the loss of a chemotherapy-free option.
“Anyone celebrating this should look themselves in the mirror; this is a tool that has just been removed from our arsenal. However, the FDA did exactly what the system is designed to do; pull back if the Ph III doesnt pan out after accelerated approval.”
— @GIMedOnc · Adagrasib withdrawal · View post ↗📌 Amplified by @KolPulseAI
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The PSMAddition trial of Pluvicto plus an androgen receptor pathway inhibitor (ARPI) in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC) showed a radiographic progression-free survival hazard ratio of 0.72, with overall survival data remaining immature. Other discussions highlight a finding that only about 6% of all bladder cancer trials have a surgical focus, as well as the expansion of PSMA imaging and theranostics in China.
“• rPFS HR 0.72 (0.58–0.90); medians NR both arms”
— @oncologytube · PSMAddition Trial · View post ↗
“In our study, only about 6% of all bladder cancer trials had a surgical focus.”
— @kor_shah · Bladder Cancer Trial Design · View post ↗
“📌 Improved reg approval 📌Participation in PSMAddition 📌Big pipeline of new isotopes/targets 📌Domestic innovation and ongoing trials”
— @zklaassen_md · PSMA Theranostics in China · View post ↗New publications in *Haematologica* explore the efficacy and safety of bridging regimens for CAR T-cell therapy in multiple myeloma, and the use of CAR-T for plasma cell leukemia. The myeloma/hematology community is also paying tribute to the passing of Dr. Robert A. Kyle, credited with foundational research in MGUS and myeloma.
“Some people contribute to a field. A rare few define it, and, through their generosity, make it possible for generations of others to find their own path within it. Dr. Robert “Bob” Kyle was one of those rare individuals.”
— @DrOlaLandgren · Tribute to Dr. Robert Kyle · View post ↗
“Everything that any trainee has ever learned about MGUS, they learned from work led by Dr. Kyle. Truly inspiring for all of us in the myeloma field.”
— @RahulBanerjeeMD · Dr. Kyle's Legacy in MGUS · View post ↗
“Chicken or egg problem in CAR T-cell therapy: bridging.”
— @NicoGagelmann · CAR-T Bridging Therapy · View post ↗The phase 2 PARADIGM trial showed azacitidine-venetoclax improved event-free survival over intensive chemotherapy (14.5 vs 6.2 months) in fit, transplant-eligible adults with AML, though overall survival was similar. This finding, along with data from a second randomized trial in a younger Chinese cohort (Lu et al.), is fueling debate on expanding use beyond its FDA-approved indication for patients age ≥75 or those unfit for intensive chemotherapy, to now include fit patients with intermediate or adverse-risk, FLT3-wildtype disease. Separately, the GIMEMA AML1310 trial's final report detailed the use of peripheral blood to measure minimal residual disease by flow cytometry in adult AML.
“Bottom line: two independent prospective trials (PARADIGM, Lu et al) plus molecularly-enriched retrospective data now support VEN-based induction as a reasonable option in fit, transplant eligible, intermediate or adverse risk, FLT3 wildtype AML.”
— @TalhaBadarMD · Aza-Venetoclax in Fit AML · View post ↗
“Azacitidine–Venetoclax or 7+3 Induction for AML -- 7+3 isn't quite dead yet!”
— @MikkaelSekeres · AML Induction Debate · View post ↗
“Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial”
— @mtmdphd · Tagraxofusp in BPDCN · View post ↗